Lactoferrin (Lf), a multifunctional cationic glycoprotein synthesized by exocrine glands and neutrophils, possesses an in vitro antiviral activity against SARS-CoV-2. Thus, we conducted an in vivo preliminary study to investigate the antiviral effect of oral and intranasal liposomal bovine Lf (bLf) in asymptomatic and mild-to-moderate COVID-19 patients. From April 2020 to June 2020, a total of 92 mild-to-moderate (67/92) and asymptomatic (25/92) COVID-19 patients were recruited and divided into three groups. Thirty-two patients (14 hospitalized and 18 in home-based isolation) received only oral and intranasal liposomal bLf; 32 hospitalized patients were treated only with standard of care (SOC) treatment; and 28, in home-based isolation, did not take any medication. Furthermore, 32 COVID-19 negative, untreated, healthy subjects were added for ancillary analysis. Liposomal bLf-treated COVID-19 patients obtained an earlier and significant (p < 0.0001) SARS-CoV-2 RNA negative conversion compared to the SOC-treated and untreated COVID-19 patients (14.25 vs. 27.13 vs. 32.61 days, respectively). Liposomal bLf-treated COVID-19 patients showed fast clinical symptoms recovery compared to the SOC-treated COVID-19 patients. In bLf-treated patients, a significant decrease in serum ferritin, IL-6, and D-dimers levels was observed. No adverse events were reported. These observations led us to speculate a potential role of bLf in the management of mild-to-moderate and asymptomatic COVID-19 patients.

Lactoferrin as antiviral treatment in COVID-19 management : Preliminary evidence / E. Campione, C. Lanna, T. Cosio, L. Rosa, M.P. Conte, F. Iacovelli, A. Romeo, M. Falconi, C. Del Vecchio, E. Franchin, M.S. Lia, M. Minieri, C. Chiaramonte, M. Ciotti, M. Nuccetelli, A. Terrinoni, I. Iannuzzi, L. Coppeta, A. Magrini, S. Bernardini, S. Sabatini, F. Rosapepe, P.L. Bartoletti, N. Moricca, A. Di Lorenzo, M. Andreoni, L. Sarmati, A. Miani, P. Piscitelli, E. Squillaci, P. Valenti, L. Bianchi. - In: INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH. - ISSN 1661-7827. - 18:20(2021 Oct), pp. 10985.1-10985.15. [10.3390/ijerph182010985]

Lactoferrin as antiviral treatment in COVID-19 management : Preliminary evidence

A. Miani;
2021

Abstract

Lactoferrin (Lf), a multifunctional cationic glycoprotein synthesized by exocrine glands and neutrophils, possesses an in vitro antiviral activity against SARS-CoV-2. Thus, we conducted an in vivo preliminary study to investigate the antiviral effect of oral and intranasal liposomal bovine Lf (bLf) in asymptomatic and mild-to-moderate COVID-19 patients. From April 2020 to June 2020, a total of 92 mild-to-moderate (67/92) and asymptomatic (25/92) COVID-19 patients were recruited and divided into three groups. Thirty-two patients (14 hospitalized and 18 in home-based isolation) received only oral and intranasal liposomal bLf; 32 hospitalized patients were treated only with standard of care (SOC) treatment; and 28, in home-based isolation, did not take any medication. Furthermore, 32 COVID-19 negative, untreated, healthy subjects were added for ancillary analysis. Liposomal bLf-treated COVID-19 patients obtained an earlier and significant (p < 0.0001) SARS-CoV-2 RNA negative conversion compared to the SOC-treated and untreated COVID-19 patients (14.25 vs. 27.13 vs. 32.61 days, respectively). Liposomal bLf-treated COVID-19 patients showed fast clinical symptoms recovery compared to the SOC-treated COVID-19 patients. In bLf-treated patients, a significant decrease in serum ferritin, IL-6, and D-dimers levels was observed. No adverse events were reported. These observations led us to speculate a potential role of bLf in the management of mild-to-moderate and asymptomatic COVID-19 patients.
Bovine lactoferrin; COVID-19; D-dimers; Ferritin; IL-6; Liposomal bovine lactoferrin; SARS-CoV-2
Settore MED/50 - Scienze Tecniche Mediche Applicate
Article (author)
File in questo prodotto:
File Dimensione Formato  
ijerph-18-10985.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 789.88 kB
Formato Adobe PDF
789.88 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/877572
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 17
social impact